Plasma cell neoplasm

This study compares three different flu vaccines in 60 adults with blood cancers like leukemia or lymphoma. The goal is to see which vaccine triggers the strongest immune response in people with weakened immune systems. Participants will receive one of the vaccines and have their…

This study tests an experimental drug, HDP-101, in people with multiple myeloma or related plasma cell disorders. The goal is to see if the drug is safe and can shrink tumors. Participants have already tried other treatments, including stem cell transplant or are not eligible for…

This study tests a new drug called elranatamab for people with multiple myeloma that has returned or stopped responding to treatment. Half of the 492 participants will get elranatamab as a weekly shot; the other half will get one of several standard drug combinations. The goal is…

This trial tests a new approach for people with multiple myeloma that has come back or not responded to treatment. Doctors take immune cells from donated cord blood, genetically engineer them to better recognize and attack myeloma cells, and give them back to the patient along wi…

This early-stage trial tests an experimental oral drug called KTX-1001 in people with multiple myeloma that has returned or not responded to prior treatments. The drug works by blocking a protein that helps myeloma cells grow. The study will enroll 165 adults and will also test K…

This study tests a drug called cosibelimab in 80 people with advanced skin cancer who also have a kidney transplant or a blood cancer. The drug works by helping the immune system attack cancer cells. Researchers will check if the tumors shrink and monitor for side effects.

This phase 3 trial is for people newly diagnosed with multiple myeloma who are not healthy enough for a stem cell transplant. After six months of standard treatment with daratumumab, lenalidomide, and dexamethasone, participants are assigned to different immunotherapy combination…

This early-phase study tests a new treatment called CAR BCMA-CD70 CAR-T for people with high-risk plasma cell neoplasms, a type of blood cancer. The therapy uses the patient's own immune cells, modified to target two cancer markers (BCMA and CD70), to attack the disease. The main…

This phase 1 trial is testing a new way to dose the chemotherapy drug melphalan for people with multiple myeloma who are getting a stem cell transplant. Instead of a standard dose, the amount is personalized based on each patient's blood levels after a test dose. The goal is to f…

This study is for people with a high-risk form of smoldering multiple myeloma, an early stage of blood cancer. The purpose is to test a drug called belantamab mafodotin to find the safest dose and see if it can control the disease. About 30 participants will receive the drug, and…

This early-phase trial is testing a new type of gene therapy called CAR 70-BCMA dual-target CAR-T for people with relapsed or refractory plasma cell neoplasms, including multiple myeloma. The therapy involves taking a patient's own immune cells, re-engineering them to recognize a…

This early-phase trial tests whether high-dose vitamin C, combined with a lower dose of the chemotherapy drug melphalan and a stem cell transplant, is safe and effective for people with relapsed multiple myeloma. The study enrolls 18 adults who have already tried at least three p…

This early-phase study tests a new drug, HDP-101, in Chinese patients with multiple myeloma or similar plasma cell disorders. The goal is to find a safe dose and see if the drug can help control the cancer. About 15 adults who have already tried other treatments will take part.

This study tests whether radiation therapy can help control multiple myeloma that remains active after standard CAR-T cell therapy. About 30 adults who still have signs of myeloma on scans after CAR-T will receive targeted radiation to up to five tumor spots. Researchers will mea…

This study tests whether adding two drugs (elotuzumab and iberdomide) plus a steroid after CAR T-cell therapy can help control multiple myeloma that has come back or not responded to treatment. About 49 adults who have already tried at least four other treatments will take part. …

This phase 2 trial tests whether the drug elranatamab, given as maintenance therapy after CAR-T cell treatment (cilta-cel), can delay cancer progression in people with high-risk relapsed myeloma. The study enrolls 39 patients whose myeloma has features like high-risk mutations or…

This study compares immunoglobulin (given through a vein or under the skin) with antibiotics to see which better prevents severe infections in people with blood cancers like myeloma, lymphoma, or leukemia who have low antibody levels. About 900 adults will take part. The goal is …

This study compares two infection-prevention strategies in 900 people with blood cancers like myeloma and leukemia. One group gets an antibiotic (co-trimoxazole) daily, while another receives immunoglobulin infusions every few weeks. The goal is to see which approach better preve…

This study compares different ways to prevent infections in people with blood cancers like myeloma, leukemia, and lymphoma. About 900 participants will receive either daily antibiotics or immunoglobulin therapy, or a combination. The goal is to see which approach works best to ke…

This study looks at different ways to prevent serious infections in people with blood cancers like myeloma, lymphoma, and leukemia. About 900 participants will receive either antibiotics or immunoglobulin therapy to see which approach works best. The goal is to find safer and mor…

This phase 2 trial tests whether combining radiation with a bispecific antibody called CM336 can safely treat solitary bone plasmacytoma, a rare plasma cell tumor that often turns into multiple myeloma. The study will enroll 21 adults with mild bone marrow involvement. Researcher…

This study aims to detect multiple myeloma at its earliest stage, called MGUS, using a simple blood test. It will screen 1,665 Black adults and close relatives of people with plasma cell disorders. The goal is to reduce delayed diagnosis and improve outcomes by catching the disea…

This study will test a new type of PET/CT scan that uses a special tracer to find BCMA, a protein on myeloma cells. The goal is to see if this scan can more accurately detect active myeloma throughout the body compared to standard methods. About 300 people with suspected or known…

This study tests whether a fecal microbiota transplant (FMT) can prevent graft-versus-host disease (GvHD) in 150 adults with blood cancers who receive a stem cell transplant. Patients get a single FMT enema within four weeks of transplant. The main goal is to see if FMT improves …

This pilot study is testing whether music therapy delivered over video calls is a practical way to help blood cancer survivors who have trouble with memory, attention, and thinking. Researchers will enroll 60 adults who have had lymphoma, leukemia, or myeloma. Participants will e…

This study tests a home-based telerehabilitation program for adults with lymphoma or myeloma who have received CAR-T cell therapy. Participants use a tablet or VR headset, along with a pulse oximeter and Fitbit, to follow personalized exercise and nutrition plans. The goal is to …

This study tests whether people with multiple myeloma can safely give themselves a standard chemotherapy drug (bortezomib) at home, instead of going to a clinic. About 100 stable patients who have already had at least four injections in a hospital will be taught to self-inject. T…

This study tests whether giving the drug daratumumab as a shot in the upper thigh works as well as the usual shot in the abdomen for people with plasma cell disorders like multiple myeloma. The goal is to find a less painful or more accessible injection spot. About 30 adults will…

This study tests a new program that gives blood cancer patients access to blood transfusions at home while they receive hospice care. The goal is to see if this improves their quality of life, mood, and reduces hospital visits near the end of life. The trial will include 700 adul…

This study provides ongoing check-ups for people who received a donor stem cell transplant at the NIH at least three years ago. Researchers will monitor for late side effects, disease return, and overall health. Participants will have yearly visits that may include blood tests, b…

This study looks back at the experiences of 60 adults with relapsed or refractory multiple myeloma who received a stem cell transplant from a donor. The goal is to measure how long patients live without their cancer progressing after this procedure. By gathering real-world data, …

This observational study will follow 30 multiple myeloma patients receiving a standard CAR-T therapy called cilta-cel. Researchers will collect blood, bone marrow, and other samples to find biomarkers linked to rare toxicities like nerve damage, blood issues, and gut problems. Th…

This study is building a large database of information from thousands of people with plasma cell disorders, including multiple myeloma and related conditions. By tracking their health over many years, researchers hope to identify patterns that predict how the disease will progres…

This study looks at whether firefighters' exposure to hazardous chemicals leads to pre-cancerous changes in their blood. Researchers will collect blood samples from 300 firefighters aged 40-49 with at least 5 years on the job. The goal is to find early markers that might predict …

This study is building a huge registry of information and biological samples from adults with or at risk for many types of cancer, as well as healthy volunteers. Researchers will use this resource to study what causes cancer and how to better prevent, detect, and treat it. The re…

This research study creates a registry of older adults with cancer to collect information about their health, treatments, and outcomes. Participants complete a geriatric assessment and allow researchers to follow their medical records. The goal is to better understand how cancer …

This study is testing how to safely perform skin allergy tests in people receiving biotherapies for cancers and blood disorders. Researchers will find the highest concentration of each biotherapy that does not cause a skin reaction in 9 out of 10 patients. The goal is to establis…

This study tests whether a special PET scan (18F FLT) can detect signs of leukemia or myeloma after treatment. About 60 people aged 4 to 80 with relapsed or hard-to-treat blood cancers will get the scan before and after therapy. Researchers will compare the scan results with stan…

This study observes older patients (60+) receiving standard CAR-T therapy for blood cancers. Researchers track how treatment affects daily activities, thinking skills, and overall quality of life. No extra treatments are given—just careful monitoring to learn more about patient e…

This study is creating a database of up to 5,000 people in Ohio with plasma cell disorders like multiple myeloma and amyloidosis. Researchers will track treatments, outcomes, and quality of life, while also offering patients access to expert consultations and information about su…

This study looks at the gut microbiome (the bacteria living in the digestive system) of people with POEMS syndrome, multiple myeloma, MGUS, AL amyloidosis, and healthy household members. Participants provide stool samples at home using a collection kit. The goal is to understand …

This study looks at how services from Blood Cancer United (formerly The Leukemia & Lymphoma Society) affect people with blood cancers like leukemia, lymphoma, and myeloma. Researchers will track 400 patients over time to see if the organization helps with access to care, quality …

This study aims to create a large collection of blood samples from 2,500 people with or at high risk for cancer. Researchers will use these samples to study liquid biopsies, which are blood tests that may help detect cancer, track treatment response, and spot recurrence. Particip…

This study is creating a large collection of blood samples, tissue, and health information from 2,500 people with plasma cell disorders like multiple myeloma. Researchers will use this repository to better understand how the disease develops and changes over time. No new treatmen…

This study collects blood, tissue, and body fluid samples from up to 15,000 people with blood cancers or related disorders. The samples are stored in a central lab for future research on diagnosis, prognosis, and immune monitoring. Participants do not receive any treatment as par…